Skip to main navigation
Skip to main content

Utility Menu

  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • france
      France
      • Français
    • germany
      Germany
      • Deutsch
    • Italian flag
      Italy
      • Italiano
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English

Utility Menu

  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • france
      France
      • Français
    • germany
      Germany
      • Deutsch
    • Italian flag
      Italy
      • Italiano
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English
Home

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
    • Mucopolysaccharidosis Type IIIA
    • Charcot-Marie-Tooth Disease
  • Our Science
    • Gene Therapy Engine
    • RNA Platform
    • Gene Editing
    • Manufacturing
    • Strategic Partnerships
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Affairs
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

Social Links

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Stock Quote

  • Home
  • Investor Relations
  • Stock Information
  • Stock Quote

IR Menu

IR Home
Press Releases
Events & Presentations
Corporate Governance
Stock Information
SEC Filings
Analyst Coverage
Information Request
FAQs

Tertiary Nav - Stock Information

  • Stock Quote
  • Stock Chart
  • Historical Price Lookup
  • Investment Calculator

Stock Quote

Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

 

Data Provided by Refinitiv. Minimum 15 minutes delayed.

 

 

Toolkit

Print Page | Email Alerts | RSS Feeds | Contacts

Follow Us On Social

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
    • Mucopolysaccharidosis Type IIIA
    • Charcot-Marie-Tooth Disease
  • Our Science
    • Gene Therapy Engine
    • RNA Platform
    • Gene Editing
    • Manufacturing
    • Strategic Partnerships
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Affairs
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

©2021 Sarepta Therapeutics All rights reserved.

Footer Utility Nav

  • Privacy Policy
  • Terms of Use
  • EU-U.S. and Swiss-U.S. Privacy Shield Policy